Quick Answer
NEUROCRINE BIOSCIENCES INC reported Research And Development Expense of $160.52 million for the year ending 2018.
- NEUROCRINE BIOSCIENCES INC showed an increase of +31.8% in Research And Development Expense from 2017 to 2018.
- This data is from NEUROCRINE BIOSCIENCES INC's annual report (Form 10-K), filed with the SEC on February 8, 2019.
- XBRL data for this metric is available from 2009 to 2018 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $7.28 million | Q3 2010: $8.23 million | Q1 2011: $7.32 million | Q2 2011: $8.18 million | Q3 2011: $7.46 million | Q1 2012: $9.39 million | Q2 2012: $8.82 million | Q3 2012: $9.86 million | Q1 2013: $10.31 million | Q2 2013: $10.53 million | Q3 2013: $9.49 million | Q1 2014: $8.57 million | Q2 2014: $10.16 million | Q3 2014: $12.19 million | Q1 2015: $16.58 million | Q2 2015: $18.72 million | Q3 2015: $24.39 million | Q1 2016: $23.90 million | Q2 2016: $26.86 million | Q3 2016: $20.94 million | Q1 2017: $51.88 million | Q2 2017: $21.87 million | Q3 2017: $22.46 million | Q1 2018: $48.95 million | Q2 2018: $36.99 million | Q3 2018: $35.48 million | Q1 2019: $37.65 million | Q2 2019: $61.69 million | Q1 2020: $58.30 million | Q1 2021: $73.20 million.
- Over the full 10 years of available data (2009 to 2018), NEUROCRINE BIOSCIENCES INC's Research And Development Expense has grown by 376.0%.
- Historical annual values: Fiscal year 2018: $160.52 million | Fiscal year 2017: $121.83 million | Fiscal year 2016: $94.29 million | Fiscal year 2015: $81.49 million | Fiscal year 2014: $46.43 million | Fiscal year 2013: $39.25 million | Fiscal year 2012: $37.16 million | Fiscal year 2011: $30.95 million | Fiscal year 2010: $31.15 million | Fiscal year 2009: $33.72 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: